Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunrise Trial: Adebrelimab and Fuzuloparib in Platinum-Resistant Ovarian Cancer
NCT06600841Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Countries
- 1
- Sponsor
- Fujian Medical University Cancer Hospital
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Conditions
- ovarian cancer
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and fluzoparib in ovarian cancer, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate at 36 months. Planned start Oct 2024; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Immunotherapy group
Adebrelimab + Fuzuloparib + Chemo induction -> Adebrelimab + Fuzuloparib maintenance
03
Who it enrols
Patients with pathologically confirmed platinum-resistant ovarian cancer (recurrence <6 months after last platinum) and confirmed HRR gene mutation.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Disease Control Rate
Overall Survival
Adverse Events
Beyond the preview
Go deeper on NCT06600841.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600841.